Will inter partes review speed US generic drug entry?

Nat Biotechnol. 2017 Dec 8;35(12):1139-1141. doi: 10.1038/nbt.4036.
No abstract available

MeSH terms

  • Drug Industry / legislation & jurisprudence*
  • Drugs, Generic* / economics
  • Drugs, Generic* / supply & distribution
  • Humans
  • Patents as Topic / legislation & jurisprudence*
  • United States

Substances

  • Drugs, Generic